Evidence suggesting the role of norepinephrine deficiency in late stages of Parkinson's disease.
Neurological Clinic, Tokyo, Japan.
H
H
Narabayashi
D000978:Antiparkinson Agents / Q000627:therapeutic use; D018450:Disease Progression; D004299:Dopamine beta-Hydroxylase / Q000378:metabolism; D015103:Droxidopa / Q000627:therapeutic use; D005917:Globus Pallidus / Q000601:surgery; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D009638:Norepinephrine / Q000172:deficiency*; D010300:Parkinson Disease / Q000201:enzymology / Q000378:metabolism* / Q000503:physiopathology / Q000523:psychology / Q000628:therapy; D013788:Thalamus / Q000601:surgery
D000978:Antiparkinson Agents; D007980:Levodopa; D004299:Dopamine beta-Hydroxylase; D015103:Droxidopa; D009638:Norepinephrine